ID16489A - Pemakaian 4-amino-4-(4-flourobenzilamino)-1-etoksi-karbonlaminobenzena untuk pencegahan penyakit dan pengobatan akibat turunnya pasokan darah yang berhubungan dengan bagian otak pada keadaan kronik dan akut dan pengobatan penyakit neurodegeneratif - Google Patents

Pemakaian 4-amino-4-(4-flourobenzilamino)-1-etoksi-karbonlaminobenzena untuk pencegahan penyakit dan pengobatan akibat turunnya pasokan darah yang berhubungan dengan bagian otak pada keadaan kronik dan akut dan pengobatan penyakit neurodegeneratif

Info

Publication number
ID16489A
ID16489A IDP963059A ID963059A ID16489A ID 16489 A ID16489 A ID 16489A ID P963059 A IDP963059 A ID P963059A ID 963059 A ID963059 A ID 963059A ID 16489 A ID16489 A ID 16489A
Authority
ID
Indonesia
Prior art keywords
treatment
flourobenzilamino
ethoksi
carbonlaminobenzena
achievement
Prior art date
Application number
IDP963059A
Other languages
English (en)
Indonesian (id)
Inventor
Angelika Rostock
Chris Rundfeldt
Christine Tober
Reni Bartsch
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of ID16489A publication Critical patent/ID16489A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IDP963059A 1995-10-26 1996-10-24 Pemakaian 4-amino-4-(4-flourobenzilamino)-1-etoksi-karbonlaminobenzena untuk pencegahan penyakit dan pengobatan akibat turunnya pasokan darah yang berhubungan dengan bagian otak pada keadaan kronik dan akut dan pengobatan penyakit neurodegeneratif ID16489A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19539861A DE19539861A1 (de) 1995-10-26 1995-10-26 Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen

Publications (1)

Publication Number Publication Date
ID16489A true ID16489A (id) 1997-10-02

Family

ID=7775835

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP963059A ID16489A (id) 1995-10-26 1996-10-24 Pemakaian 4-amino-4-(4-flourobenzilamino)-1-etoksi-karbonlaminobenzena untuk pencegahan penyakit dan pengobatan akibat turunnya pasokan darah yang berhubungan dengan bagian otak pada keadaan kronik dan akut dan pengobatan penyakit neurodegeneratif

Country Status (26)

Country Link
US (2) US5852053A (ja)
EP (1) EP0857065B1 (ja)
JP (2) JP4567101B2 (ja)
KR (1) KR100423823B1 (ja)
AR (1) AR004108A1 (ja)
AT (1) ATE178487T1 (ja)
AU (1) AU706735B2 (ja)
BR (1) BR9610899A (ja)
CA (1) CA2188841C (ja)
CZ (1) CZ291456B6 (ja)
DE (2) DE19539861A1 (ja)
DK (1) DK0857065T3 (ja)
ES (1) ES2131973T3 (ja)
GR (1) GR3030336T3 (ja)
HU (1) HU228014B1 (ja)
ID (1) ID16489A (ja)
IL (1) IL123523A (ja)
NO (1) NO316493B1 (ja)
NZ (1) NZ326754A (ja)
PL (1) PL185714B1 (ja)
RU (1) RU2201227C2 (ja)
SK (1) SK283222B6 (ja)
TW (1) TW457084B (ja)
UA (1) UA51681C2 (ja)
WO (1) WO1997015300A2 (ja)
ZA (1) ZA968991B (ja)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19539861A1 (de) * 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
US6472165B1 (en) * 1999-08-03 2002-10-29 Arzneimittelwerk Dresden Gmbh Modulatory binding site in potassium channels for screening and finding new active ingredients
US6117900A (en) * 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
TWI287984B (en) 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function
US6589986B2 (en) * 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
AU2002338333A1 (en) * 2001-04-04 2002-10-21 Wyeth Methods for treating hyperactive gastric motility
US7205307B2 (en) * 2002-02-14 2007-04-17 Icagen, Inc. Pyrimidines as novel openers of potassium ion channels
PL377221A1 (pl) * 2002-12-27 2006-01-23 H. Lundbeck A/S Pochodne 1,2,4-triaminobenzenu
DK1578740T3 (da) * 2002-12-27 2007-07-30 Lundbeck & Co As H 1,2,4-triaminobenzenderivater, der er egnede til behandling af lidelser i centralnervesystemet
EP1631546A1 (en) * 2003-04-25 2006-03-08 H. Lundbeck A/S Sustituted indoline and indole derivatives
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
TWI357901B (en) 2004-03-12 2012-02-11 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivati
AU2006220130B2 (en) 2005-03-03 2011-07-28 H. Lundbeck A/S Substituted pyridine derivatives
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) * 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
PT2061465E (pt) * 2006-08-23 2013-07-15 Valeant Pharmaceuticals Int Derivados de 4-(n-azacicloalquil)anilidas como moduladores do canal de potássio
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
US8030518B2 (en) * 2006-11-28 2011-10-04 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
WO2010009433A1 (en) * 2008-07-18 2010-01-21 Valeant Pharmaceuticals International Modified release formulation and methods of use
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
WO2013011518A1 (en) 2011-07-21 2013-01-24 Arch Pharmalabs Limited Process for the preparation of retigabine of the formula i and pharmaceutically acceptable salts thereof
CN103073455B (zh) 2011-10-25 2015-08-19 中国科学院上海药物研究所 一类新型的kcnq钾通道激动剂、其制备方法和用途
EP2882429B1 (en) * 2012-08-07 2024-04-10 The General Hospital Corporation Potassium-channel openers for use in treating amyotrophic lateral sclerosis (ALS)
CN105017085B (zh) 2014-04-28 2018-06-29 中国科学院上海药物研究所 一类kcnq钾通道激动剂、其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2817334B2 (ja) * 1990-03-29 1998-10-30 株式会社ツムラ 神経細胞保護剤
DE4200259A1 (de) * 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
DE4327516A1 (de) * 1993-08-17 1995-02-23 Asta Medica Ag Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin
TW280819B (ja) * 1993-11-17 1996-07-11 Sumitomo Pharma
DE19539861A1 (de) * 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen

Also Published As

Publication number Publication date
GR3030336T3 (en) 1999-09-30
WO1997015300A3 (de) 1997-07-03
JPH11515007A (ja) 1999-12-21
AR004108A1 (es) 1998-09-30
NO981503L (no) 1998-04-02
PL185714B1 (pl) 2003-07-31
EP0857065A2 (de) 1998-08-12
TW457084B (en) 2001-10-01
CZ122598A3 (cs) 1998-09-16
NO316493B1 (no) 2004-02-02
HUP9900508A2 (hu) 1999-06-28
EP0857065B1 (de) 1999-04-07
WO1997015300A2 (de) 1997-05-01
CA2188841A1 (en) 1997-04-27
UA51681C2 (uk) 2002-12-16
HUP9900508A3 (en) 1999-11-29
SK52098A3 (en) 1998-09-09
MX9803172A (es) 1998-09-30
DE19539861A1 (de) 1997-04-30
JP4567101B2 (ja) 2010-10-20
AU706735B2 (en) 1999-06-24
AU1540097A (en) 1997-05-15
US5849789A (en) 1998-12-15
ES2131973T3 (es) 1999-08-01
RU2201227C2 (ru) 2003-03-27
BR9610899A (pt) 1999-07-13
HU228014B1 (en) 2012-08-28
SK283222B6 (sk) 2003-03-04
IL123523A0 (en) 1998-10-30
PL325956A1 (en) 1998-08-17
ZA968991B (en) 1997-06-10
CA2188841C (en) 2006-05-23
DK0857065T3 (da) 1999-10-18
KR100423823B1 (ko) 2004-08-25
NO981503D0 (no) 1998-04-02
US5852053A (en) 1998-12-22
JP2009007366A (ja) 2009-01-15
CZ291456B6 (cs) 2003-03-12
NZ326754A (en) 2000-03-27
DE59601624D1 (de) 1999-05-12
ATE178487T1 (de) 1999-04-15
IL123523A (en) 2001-12-23
KR19990067021A (ko) 1999-08-16

Similar Documents

Publication Publication Date Title
ID16489A (id) Pemakaian 4-amino-4-(4-flourobenzilamino)-1-etoksi-karbonlaminobenzena untuk pencegahan penyakit dan pengobatan akibat turunnya pasokan darah yang berhubungan dengan bagian otak pada keadaan kronik dan akut dan pengobatan penyakit neurodegeneratif
DE69838338D1 (de) Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
HK1005985A1 (en) Combined use of hyaluronic acid and therapeutic agents to improve the therapeutic effect
ATE229502T1 (de) Arylsulfonamide und analoga und ihre verwendung zur behandlung von neurodegenerativen erkrankungen
DE50004178D1 (de) Therapiebandage
DK0668763T3 (da) Anvendelse af phenserin til fremstillingen af lægemidler til behandlingen af kognitive sygdomme
IL121268A0 (en) Branched chain fatty acids their derivatives and use in the treatment of central nervous system disorders
EE04055B1 (et) Ühendid ja kompositsioonid seriinproteaasse, eriti trüptaasse aktiivsusega seotud haiguste raviks, ja nende kasutamine
EE9700361A (et) Meetod silma närvi ja võrkkesta verevoolu kiiruse suurendamiseks
HK1037980A1 (en) Use of selegiline or desmethylselegiline for the manufacture of a medicament for treating wounds, burns or photodamage.
NO995231D0 (no) Terapeutisk behandling av hudlidelser
ID20284A (id) Pesawat penyalur yang mampu untuk menghindarkan kelainan pada jumlah yang disalurkan serta memperbaiki keadaan kesehatan
FI941345A0 (fi) Retinoidit ja niiden käyttö ihosairauksien ja leukemian hoitoon
FI973185A0 (fi) Melatoniinin käyttö lääkeriippuvuudesta kärsivien potilaiden hoitoon
EP0147185A3 (en) Therapeutic use of cytidyl disphosphocholine to increase neuronal acetylcholine
NZ291053A (en) Method to maximise the health of the optic nerve and retina by using a beta-adrenergic blocking agent
HUP0000785A3 (en) Ointment for the treatment of burns and other skin diseases
NO960545D0 (no) Behandling av skadelige virkninger i forbindelse med administrering av ekstracellulært hemoglobin
AU8799398A (en) Physiological combination of active substances to enhance the skin's defenses against noxious agents
ZA9610584B (en) Use of rc-9 in diagnosis and treatment of proliferative arterial disease
NO960866L (no) Fremgangsmåte til behandling av leversykdom og lignende indikasjoner med vasodilaterende midler
DE60019166D1 (de) Verwendung von adatanserin zur behandlung von akuten neurodegenerativen erkrankungen
GB9401745D0 (en) Improvements in and relating to the administration of medicaments or therapeutic substances
EP0720849A3 (en) Agents for inhibiting the production of IL-1beta and the release of TNFalpha
EP0456204A3 (en) Use of benzocycloheptathiophenecarboxylic acid derivatives in the treatment of eosinophile accumulation/activation and connected diseases